BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome DOI Creative Commons
Yang Shen, Ying Dong, Jie Jiao

и другие.

Vaccines, Год журнала: 2023, Номер 11(5), С. 942 - 942

Опубликована: Май 4, 2023

Several observational studies have confirmed that the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) might substantially affect gastrointestinal (GI) system by replicating in human small intestine enterocytes. Yet, so far, no study has reported effects of inactivated SARS-CoV-2 virus vaccines on gut microbiota alterations. In this study, we examined BBIBP-CorV vaccine (ChiCTR2000032459, sponsored Beijing Institute Biological Products/Sinopharm), microbiota. Fecal samples were collected from individuals whoreceived two doses intramuscular injection and matched unvaccinated controls. DNA extracted fecal was subjected to 16S ribosomal RNA sequencing analysis. The composition biological functions between vaccinated compared. Compared with controls, subjects exhibited significantly reduced bacterial diversity, elevated firmicutes/bacteroidetes (F/B) ratios, a tendency towards Faecalibacterium-predominant enterotypes, altered microbial compositions functional potentials. Specifically, intestinal recipients enriched Faecalibacterium Mollicutes lower abundance Prevotella, Enterococcus, Leuconostocaceae, Weissella. Microbial function prediction phylogenetic investigation communities using reconstruction unobserved states (PICRUSt) analysis further indicated Kyoto Encyclopedia Genes Genomes (KEGG) pathways involved carbohydrate metabolism transcription positively associated inoculation, whereas capacities neurodegenerative diseases, cardiovascular cancers negatively affected vaccines. Vaccine inoculation particularly alterations, as demonstrated improved

Язык: Английский

Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore DOI Open Access

M Premikha,

Calvin J. Chiew, Wycliffe Enli Wei

и другие.

Clinical Infectious Diseases, Год журнала: 2022, Номер 75(8), С. 1442 - 1445

Опубликована: Апрель 12, 2022

Compared with individuals vaccinated Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI, 2.29-2.46) 1.62 1.43-1.85) times more likely to be infected coronavirus disease 19, respectively, while Moderna 0.42 0.25-0.70) less develop severe disease.

Язык: Английский

Процитировано

74
The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection DOI Creative Commons

Christina M. Arieta,

Yushu Joy Xie,

Daniel Rothenberg

и другие.

Cell, Год журнала: 2023, Номер 186(11), С. 2392 - 2409.e21

Опубликована: Апрель 13, 2023

T cell responses play an important role in protection against beta-coronavirus infections, including SARS-CoV-2, where they associate with decreased COVID-19 disease severity and duration. To enhance immunity across epitopes infrequently altered SARS-CoV-2 variants, we designed BNT162b4, mRNA vaccine component that is intended to be combined BNT162b2, the spike-protein-encoding vaccine. BNT162b4 encodes variant-conserved, immunogenic segments of nucleocapsid, membrane, ORF1ab proteins, targeting diverse HLA alleles. elicits polyfunctional CD4+ CD8+ animal models, alone or when co-administered BNT162b2 while preserving spike-specific immunity. Importantly, demonstrate protects hamsters from severe reduces viral titers following challenge variants. These data suggest a combination could reduce duration caused by circulating future currently being clinically evaluated BA.4/BA.5 Omicron-updated bivalent (NCT05541861).

Язык: Английский

Процитировано

61
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines DOI
Saeed Khoshnood,

Maniya Arshadi,

Sousan Akrami

и другие.

Journal of Clinical Laboratory Analysis, Год журнала: 2022, Номер 36(5)

Опубликована: Апрель 14, 2022

Abstract After about 2 years since severe acute respiratory syndrome coronavirus (SARS‑CoV‑2), first infections were detected in Wuhan city of China December 2019, which was followed by a worldwide pandemic with record 5.41 million deaths. Due to urgent need for the development safe and effective vaccine disease 2019 (COVID‐19), attempts producing efficient vaccines are inexhaustibly continuing. According report World Health Organization (WHO) on COVID‐19 tracker landscape, there 149 candidates all over world. Inactivated SARS‐CoV‐2 as conventional platform consist whole virus particles grown cell culture inactivated chemicals. Because benefits such antigenic similarity real virion inducing humoral cellular immune responses ease transport storage, these vaccines, including produced Bharat Biotech, Sinopharm, Sinovac, use at large scales. In this study, we have review that passing their phase 3 4 clinical trials, population included producers, efficiency, adverse effects, components other features.

Язык: Английский

Процитировано

66
Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study DOI Creative Commons
Vincent Ka Chun Yan, Eric Yuk Fai Wan, Xuxiao Ye

и другие.

Emerging Microbes & Infections, Год журнала: 2022, Номер 11(1), С. 2304 - 2314

Опубликована: Авг. 18, 2022

Data regarding protection against mortality and severe complications after Omicron BA.2 infection with CoronaVac BNT162b2 vaccines remains limited. We conducted a case-control study to evaluate the risk of following 1-3 doses using electronic health records database. Cases were adults their first COVID-19-related or between 1 January 31 March 2022, matched up-to 10 controls by age, sex, index date, Charlson Comorbidity Index. Vaccine effectiveness type number was estimated conditional logistic regression adjusted for comorbidities medications. (95% CI) two 90.7% (88.6-92.3) 74.8% (72.5-76.9) in those aged ≥65, 87.6% (81.4-91.8) 80.7% (72.8-86.3) 50-64, 86.6% (71.0-93.8) 82.7% (56.5-93.1) 18-50. 82.1% (74.6-87.3) 58.9% (50.3-66.1) 83.0% (69.6-90.5) 67.1% (47.1-79.6) 78.3% (60.8-88.0) 77.8% (49.6-90.2) Further reduction third dose observed especially ≥65 years, vaccine 98.0% (96.5-98.9) 95.5% (93.7-96.8) mortality, 90.8% (83.4-94.9) 88.0% (80.8-92.5) complications. Both vaccination effective amidst pandemic, risks decreased further dose.

Язык: Английский

Процитировано

47
Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines DOI
Carlos King Ho Wong, Lung‐Yi Mak, Ivan Chi Ho Au

и другие.

Journal of Hepatology, Год журнала: 2022, Номер 77(5), С. 1339 - 1348

Опубликована: Июль 9, 2022

Язык: Английский

Процитировано

43
Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh DOI Creative Commons
Md. Ahsanul Haq, Anjan Kumar Roy, Razu Ahmed

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Май 20, 2024

Abstract COVID-19 vaccines have been effective in preventing severe illness, hospitalization and death, however, the effectiveness diminishes with time. Here, we evaluated longevity of antibodies generated by COIVD-19 risk (re)infection Bangladeshi population. Adults receiving two doses AstraZeneca, Pfizer, Moderna or Sinopharm were enrolled at 2–4 weeks after second dosing followed-up 4-monthly interval for 1 year. Data on COVID-like symptoms, confirmed infection, co-morbidities, receipt booster dose collected; blood was collected measuring spike (S)- nucleocapsid (N)-specific antibodies. S-specific antibody titers reduced ~ 50% 1st follow-up visit continued to decline unless re-stimulated vaccine (re)infection. Individuals infected between visits showed significantly lower S-antibody preceding compared uninfected individuals. Pre-enrolment infection primary vaccination exhibited 60% protection against reinfection 5 9 months, respectively. mRNA provided highest odds from up months (Odds Ratio (OR) = 0.08), persisted AstraZeneca recipients (OR 0.06). In conclusion, vaccine-mediated is partially linked elevated levels longest protection.

Язык: Английский

Процитировано

11
Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza DOI Creative Commons
Xiaole Cui, Pieter Vervaeke, Ya Gao

и другие.

npj Vaccines, Год журнала: 2024, Номер 9(1)

Опубликована: Авг. 3, 2024

This study reports on the immunogenicity and biodistribution of H5 hemagglutinin (HA)-based self-amplifying (sa) mRNA vaccines in mice. Four sa-mRNA encoding either a secreted full-length HA, HA head domain, stalk or membrane-anchored were investigated. All elicited an adaptive immune response. However, sa-RNA demonstrated superior performance compared to domain vaccines. The antibody titers positively correlated with vaccine dose. Cellular responses antigen-specific IgA antibodies lungs also observed. comparison revealed that anchoring membrane significantly enhanced cellular responses. In addition injection site, intramuscularly injected sa-mRNA-LNPs detected draining lymph nodes, spleen, lesser extent, lung, kidney, liver, heart.

Язык: Английский

Процитировано

10
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy DOI Creative Commons
Zsolt Matula,

Márton Gönczi,

Gabriella Bekő

и другие.

Vaccines, Год журнала: 2022, Номер 10(4), С. 539 - 539

Опубликована: Март 30, 2022

In the present study, antibody and T cell-mediated immune responses elicited by BBIBP-CorV BNT162b2 vaccines were compared 6 months after two-dose immunization of healthy individuals. Additionally, cell third dose or using a homologous heterologous vaccination strategy. The was consistently administered second dose. Six following vaccination, cumulative IFNγ-positive response almost identical in participants immunized with either two doses vaccines; however, significant differences revealed regarding humoral immunity: vaccine maintained significantly higher antireceptor-binding domain (RBD) IgG, anti-spike (S1/S2) IgA levels. + series lower anti-RBD IgG anti-S1/S2 levels than three BNT162b2, while anti-S level equally negligible both groups. Importantly, highly similar Surprisingly, provided much that BNT162b2; moreover, identical. Only mean receiving mRNA vaccines. Based on these data, we can conclude administering is an effective strategy to enhance response, its effectiveness comparable

Язык: Английский

Процитировано

33
RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine DOI Creative Commons
Tamás Ferenci, Balázs Sarkadi

BMC Infectious Diseases, Год журнала: 2022, Номер 22(1)

Опубликована: Янв. 24, 2022

Abstract Background Limited information is available on the effectiveness of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in elderly, despite fact that it approved more than 50 countries. Methods RBD-specific antibody titres, as a rapidly and highly predictive surrogate marker, were measured after two doses vaccine 450 subjects. Results analyzed multivariable model accounting for age, sex time since administration second dose vaccine. Sex had little association with titres. Age, however, was relevant: measurable levels present about 90% individuals below age 50, but production vaccination strongly reduced increasing age. A large number elderly subjects, reaching 25% at 60 years, up to 50% ages over 80, found not produce any protective antibody. Conclusions titre, correlate protection COVID-19 disease susceptibility, should help evaluate suggest proper measures be undertaken prevent potential outbreak vaccinated eventually unprotected individuals.

Язык: Английский

Процитировано

32
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273 DOI Creative Commons
Carla A. Pascuale, Augusto Varese, Diego Ojeda

и другие.

Cell Reports Medicine, Год журнала: 2022, Номер 3(8), С. 100706 - 100706

Опубликована: Авг. 1, 2022

Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about combination these platforms with other vaccines widely used developing countries, such as BBIBP-CorV Sputnik V. Here, we assess immunogenicity reactogenicity 15 1,314 participants. We evaluate immunoglobulin G (IgG) anti-spike response virus neutralizing titers observe that number heterologous equivalent or superior homologous schemes. For all cohorts this study, highest antibody induced by mRNA-1273 second dose. No serious adverse events detected any schedules analyzed. Our observations provide support for use different achieve wide shortest possible time.

Язык: Английский

Процитировано

32